Navigation Links
Appeal Proceedings on European VisionBlue Patent Stayed; Patent Remains in Force
Date:5/20/2009

ZUIDLAND, The Netherlands, May 20 /PRNewswire/ -- The Technical Board of Appeal of the European Patent Office has postponed its final decision on two appeals lodged by two competitors against an earlier decision to maintain the European patent for VisionBlue.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090520/347917-a )

(Photo: http://www.newscom.com/cgi-bin/prnh/20090520/317917-b )

Introduced in 1999, the VisionBlue product is protected by US patent US 6,720,314 and European patent EP 1 075 285. However, after the European Patent was granted, three European manufacturers of copy cat products started opposition proceedings against the European Patent. The result of these proceedings was that the patent was maintained, after which two of the opponents appealed from the decision.

The Technical Board of Appeal of the European Patent Office decided during a hearing in Munich on the 14th of May 2009 to await the answers to legal questions concerning the patentability of medical treatments before coming to a final decision on the validity of the patent. These answers from the Enlarged Board of Appeal of the European Patent Office are expected at the latest in January 2010.

Requests of the opponents to deal with their objections for lack of novelty and inventive step before the proceedings were stayed, were rejected. They argued that the patent should be revoked on these grounds and that therefore a stay of the proceedings would not be necessary. D.O.R.C. believes that the rejection of these requests is a strong indication that the Board of Appeal expects to confirm the validity of the patent once the answers to the legal questions have clarified that features of a medical treatment can be used to define patentable inventions.

In the meantime, the VisionBlue patent remains fully in force and offers the possibility to fight the sales of copies of the VisionBlue product in Europe, which may be produced under less strict quality standards. This means that D.O.R.C. remains the only company in Europe that can legally promote and sell VisionBlue, or any other staining product based on trypan blue for cataract / anterior capsule staining.

VisionBlue profile

The D.O.R.C. product 'VisionBlue' is a staining liquid, used as an aid by the eye surgeon during cataract surgery. VisionBlue facilitates the visualization of the anterior lens capsule and may prevent an incomplete removal of the anterior lens, radial capsule tears and associated complications.

VisionBlue was introduced in 1999 and is still growing in popularity among cataract surgeons. Since 2004 VisionBlue has been approved by the US FDA (Food and Drug Administration), the ultimate recognition of our product quality, which is underpinned by validated production processes stabilization studies and safety studies. VisionBlue has a safety track record of more than 3 million surgeries.

Company profile

Since the foundation in 1983, D.O.R.C. has developed into a market leader in research, development and production of products for eye surgery, especially products for vitreoretinal and cataract surgery. Our products are used by eye surgeons worldwide, because of the high quality development and because our products are known for their state-of-the-art design, quality and craftsmanship.

D.O.R.C. has its own research and development department and is receiving a continuous feedback from market developments and market queries regarding high quality eye surgery products, disposable products and electronic equipment.

D.O.R.C. has continuously engaged in worldwide cooperative undertakings with leading surgeons. These cooperations have resulted in the introduction of multiple unique products for the ophthalmic market. The innovation quote of DORC is at a level of 10% of the turnover.

D.O.R.C. exports its products to more than 90 countries worldwide, through an extensive, exclusive distributor network having its own sales offices in the USA, Middle-East, Germany, France, Scandinavia, Belgium and the Netherlands. The D.O.R.C. companies employ about 190 people.

Website: http://www.dorc.nl

Staining of the anterior lens capsule with VisionBlue.(Photographs by courtesy of Dr. G.R.J. Melles)


'/>"/>
SOURCE D.O.R.C. International b.v.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Appeals Court Affirms That J&J Stents Infringe Boston Scientific Patent; Claims Against TAXUS Liberte Dismissed
2. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
3. PreMD Reduces Staffing, Operations - FDA Appeal Still in Process
4. Apple peel appeal
5. U.S. Court of Appeals Rules That Smith & Nephew Does Not Infringe KCI Patents
6. This February Discovery en Espanol Delves Into The Subconscious World of Attraction in Science of Sex Appeal
7. QLT Announces Appeal Court Decision on Massachusetts Eye and Ear Infirmary Litigation
8. Americans United For Life Denounces Montana Courts Assisted Suicide Decision, Urges Appeal
9. Physicians Rank Schering-Ploughs Marketing Messages for Asmanex as the Most Appealing in the Asthma Drug Market
10. Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case
11. AGA Medical to Appeal Ruling by Dutch Court in Lawsuit With Occlutech GmbH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... Americans facing life-altering and fatal diseases in opposition to the President’s Fiscal ... would eviscerate care, services, and hope for the most vulnerable among us. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, ...                  , How will the new EU MDR language change the way ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... News Advisory/Interview ... Choice has helped score a major victory in Europe for public health and the ... , Based on rigorous scientific research and the overwhelming support of European citizens, ...
(Date:3/23/2017)... ... ... “My Journey Through Heaven”: the true-life account of a man who faced ... promise of Heaven for His people. “My Journey Through Heaven” is the creation of ... children and six grandchildren living and doing for God as best they can. , ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “The Trainer”: ... creation of published author, Scotty, a fiction writer with an active imagination and an ... Scotty’s new book follows the tale of Wild Bill Hart, who sat looking at ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 23, 2017 ReportsnReports.com adds Global ... research report. The global vagus nerve stimulation market analyst ... focus toward minimally invasive VNS procedures. Few years ago, ... developed countries having high standards of healthcare infrastructure. ... ...
(Date:3/22/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 10.9% over the next decade to reach approximately $38.27 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... 22, 2017  "Global Biosimilar Insulin Market ... gives comprehensive insight on clinical and non-clinical ... insulin market. This report analyzes various aspects ... of insulin in diabetes, engineering of synthetic ... with market overview, biosimilar insulin clinical pipeline ...
Breaking Medicine Technology: